Top Recommendations Announced at the Conclusion of DUPHAT 2020 Conference and Exhibition
Dubai – United Arab Emirates,
Sallam Sallam
Under the patronage of His Highness Sheikh Hamdan bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance and President of Dubai Health Authority, the 25th edition of Dubai International Pharmaceuticals and Technologies Conference and Exhibition – DUPHAT successfully concluded today at the Dubai International Convention and Exhibition Center. The 3-day premier pharma event featured a number of key scientific sessions, workshops and highly specialized sessions which focused on presenting the most up-to-date knowledge and advances in the drug manufacturing industry while also highlighting the latest laws and regulations governing the administration and efficacy of drugs in the region.
On the third and final day of DUPHAT 2020, the scientific committee had released the following recommendations:
1- Pharmaceutical regulatory and legislative authorities should adopt effective measures for analyzing the root causes for medicines shortages / limited availability, and design / set practical solutions to confront these situations jointly in coordination with local and regional industry.
2- Implement governance system and productivity indicators in pharmaceutical establishments to enable functional accountability throughout the different pharmaceutical activities and to monitor institutional compliance.
3- Encourage Pharmaceutical establishments to implement strategic planning which is a powerful tool for ensuring success for organizations. Strategic plan with flexible and adjustable operational plans should be reviewed and re-evaluated at least annually for best practice.
4- Spread awareness about pharmaceutical care in the health care organization, being a continuous system that does not end with just providing treatment and dispensing medications, but rather continues through the necessity of communicating with patients for emphasizing the importance of adhering to treatment, taking medications correctly, and ensuring the patient’s knowledge of their health status and evaluating the medical outcomes.
5- Develop advanced Pharmaceutical education methodologies to suit the accelerating technological innovation and to prepare a generation of pharmacists able to accommodate with expanding and different pharmacy practice environments, and to empower them with new and innovative tools that can help them better serve their patients and improve health outcomes.
6- Enhance pharmacists’ role in pharmacovigilance and drug management policies at community level through the inclusion of the principles of epidemiology in pharmacological practice, risk reduction strategies, and health survey as tools that pharmacists should train for.
7- Encourage the developing of research sills and advancement of knowledge between pharmacists that can lead to stimulate innovations in the field of pharmaceutical discoveries and to real advantages in actual and traditional practice.
8- Introduce to the pharmaceutical curricula the courses that highlight factors influencing the development of professional roles and responsibilities in preparation for future roles for pharmacists, and future leaderships and management needs.
9- Utilize Technological Innovations in health fields; such as patient platforms, wearables, Internet access, and telemedicine, with the goal of increasing patient participation in the care services and optimizing therapy outcomes.
10- Benefit from technological advances to enhance pharmacists’ contributions to providing advanced pharmaceutical care. In addition, invest in automation systems and artificial intelligence, genetic pharmacology and mobile health applications (telemedicine)
11- Evolving roles and responsibilities in patient care necessitate for every Pharmacy system to familiarize themselves with best practices in the field of pharmacy education, practice, and workforce development; as well as research conduction, in a goal to prepare pharmacy practitioners to be skilled for working in a professional environment.
12- Interchangeability with biosimilar products is increasing with increased number of approved such products by international accreditation bodies. there is a need to monitor the evolving challenges in biosimilars science, production and clinical outcomes.
13- Adopt Strategies to address the problem of bacterial resistance to antibiotics and rationalization of antibiotic consumption for successful treatment such as short stay in intensive care departments, right choice for antibiotics, and giving them at the right time.
14- Monitor the growing trend towards gene therapy use and biological treatments in treating and preventing diseases, and the researches and experiments to evaluate the potential major medical and economic effects of modern gene therapies
15- Quality assurance in the pharmaceutical industry remains to be the most important controlling tool to ensure product quality and safety and to avoid errors. strict tracking procedures should be implemented to ensure compatibility with international standards as well as investing in technology in monitoring the effectiveness of quality assurance processes.
DUPHAT is organized annually by INDEX Conferences and Exhibitions – a member of INDEX Holding in strategic partnership with General Directorate of Residency and Foreigners Affairs (GDRFA), Dubai Health Authority (DHA), American Society of Health-System Pharmacists, International Society for Pharmacoepidemiology, European Federation for Pharmaceutical Sciences and European Society of Clinical Pharmacy.
